Lubomir Sokol

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

Bertrand Coiffier, Barbara Pro, H. Miles Prince et al. · Journal of Clinical Oncology · 2012 · 674 citations

Medicine, Pharmacology, Pharmacotherapy +13

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 580 citations

Medicine, Hematology, Oncology +12

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

Ashley A. Basiorka, Kathy L. McGraw, Erika A. Eksioglu et al. · Blood · 2016 · 346 citations · Full text

Life Sciences, Immunology, Molecular Biology +14

Non-Hodgkin’s Lymphomas

Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani et al. · Journal of the National Comprehensive Cancer Network · 2010 · 329 citations · Full text

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

Frits van Rhee, Luis Fayad, Peter M. Voorhees et al. · Journal of Clinical Oncology · 2010 · 242 citations

Life Sciences, Hematology, Immunology +13